FDA advisors decided against recommending over-the-counter (OTC) marketing approval of Primatene HFA inhaler (Armstrong Pharmaceuticals) for the temporary relief of mild symptoms of intermittent asthma in patients 12 years and older, at last week’s joint meeting of the FDA’s Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee.
FDA advisors decided against recommending over-the-counter (OTC) marketing approval of Primatene HFA inhaler (Armstrong Pharmaceuticals) for the temporary relief of mild symptoms of intermittent asthma in patients 12 years and older, at last week’s joint meeting of the FDA’s Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee.
Eighteen members of the advisory committee voted against granting marketing approval for OTC use of Primatene HFA (epinephrine inhalation aerosol 125 µg/actuation), a replacement for the OTC Primatene Mist, which was phased out in December 2011 because of its use of chlorofluorocarbons as the propellant. Primatene HFA is a new formulation using hydrofluoroalkane (HFA), considered to be environmentally acceptable. Six members voted in favor of the new formulation and one member did not vote.
In presenting its case, Armstrong Pharmaceuticals emphasized the efficacy and safety of the new formulation of epinephrine HFA, which, if approved, would make it the only OTC metered-dose-inhaler bronchodilator on the U.S. market. At this time, the only available short-acting beta2-agonists are prescription albuterol and levalbuterol. Epinephrine was one of the first sympathomimetic agents available, and was used in the treatment of asthma dating as far back as the early 1900s.
The new formulation was significantly effective for bronchodilatory effect in asthma patients for the primary end point for all 3 study visits (day 1, week 6, and week 12), compared with placebo.
“At week 12, [the new formulation] showed significant efficacy for 15 of the 16 secondary end points for both one-sided and two-sided tests. The one secondary end point which did not demonstrate significant efficacy was âFEV1 at six hours,” the manufacturer said.
In terms of safety, the most common adverse events that occurred with the new formulation were tremor (9.7%), throat irritation (5.2%), cough (4.4%), chest discomfort (3.6%), and a jittery feeling (3.2%). Adverse events included tremor, chest discomfort and pain, tachycardia, heart rate increase, and QTc prolongation. No significant cardiovascular events were found in connection with this new formulation.
In terms of efficacy, 14 FDA committee members voted in favor of Primatene HFA, 10 voted against, and 1 abstained. In terms of safety, seven voted in favor of the new formulation, 17 voted against, and 1 abstained.
Concerns about the use of the HFA inhaler were voiced by some FDA committee members, who thought that the device needed special care to prevent inaccurate dosing and that patients might not use the inhalers as directed on the product labeling.
In the performance of the Primatene HFA label behavioral study, only 73.8% of the study participants shook the inhaler properly and only 77% washed the mouthpiece through the opening. In addition, only 63.9% were able to reassemble the inhaler.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More